jsh-23 and Adenocarcinoma

jsh-23 has been researched along with Adenocarcinoma* in 1 studies

Other Studies

1 other study(ies) available for jsh-23 and Adenocarcinoma

ArticleYear
NF-κB suppression synergizes with E7386, an inhibitor of CBP/β-catenin interaction, to block proliferation of patient-derived colon cancer spheroids.
    Biochemical and biophysical research communications, 2022, 01-01, Volume: 586

    Dysregulated activation of the WNT/β-catenin signaling pathway is essential for the initiation and development of various cancers. E7386, a small-molecule compound, attenuates WNT signaling by blocking the interaction between β-catenin and CREB-binding protein (CBP); hence, it is regarded as a therapeutic candidate for cancers with activated WNT signaling. In the present study, we evaluated the biological characteristics associated with E7386 sensitivity by using a panel of patient-derived colon cancer spheroids. An integrative approach that combined E7386 sensitivity and gene expression profiles revealed that the resistance of the cancer spheroids to E7386 was associated with the activation of the NF-κB pathway. NF-κB pathway inhibitors acted synergistically with E7386 to block proliferation and induce cell cycle arrest in E7386-resistant spheroids. These findings suggest a possibility that a combination of E7386 and NF-κB inhibition may effectively block the proliferation of a subset of colon cancer cells.

    Topics: Adenocarcinoma; beta Catenin; Cell Cycle Checkpoints; Cell Proliferation; Colonic Neoplasms; CREB-Binding Protein; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; NF-kappa B; Phenylenediamines; Primary Cell Culture; Pyrazines; Spheroids, Cellular; Triazines; Wnt Signaling Pathway

2022